Answer
Among 425 patients with cervical cancer treated with tisotumab vedotin (Tivdak), the most common gastrointestinal side effects of any grade were nausea (37%), diarrhoea (25%), constipation (24%), abdominal pain (22%) and vomiting (20%).
Sources for this answer
- TivdakGenmab A/S · emc · SmPC §4.8 Undesirable effects · Version 1Document updated
Sources checked